What it actually is
Limitless Biotech
5-Amino-1MQ
Worth clearing up first, because it affects how you read everything else. 5-Amino-1MQ is not a peptide. It is a small molecule, specifically a methylquinolinium derivative, with no amino-acid chain involved.
It appears in peptide vendor catalogues because the audience overlaps, not because it belongs to the class. Of the vendors we review, Limitless Biotech stocks it.
That distinction matters practically: it is usually taken orally as a capsule or powder rather than reconstituted and injected, so none of our reconstitution material applies to it.
The NNMT mechanism
This is the part that is genuinely interesting, and it is more specific than most mechanisms in this market.
NNMT is nicotinamide N-methyltransferase, an enzyme that is elevated in fat tissue in obesity. The research hypothesis is that high NNMT activity consumes nicotinamide and suppresses NAD+ availability in fat cells, lowering their metabolic rate.
Inhibit NNMT and the proposal is that fat cells recover metabolic activity. 5-Amino-1MQ is an NNMT inhibitor, and in mouse studies that chain of reasoning produced reduced fat mass without reducing food intake.
That is a coherent, falsifiable mechanism with animal data supporting it. It puts the compound ahead of most things marketed for fat loss on rationale alone.
What is missing
Everything after the mouse, and the gap is larger than usual.
| Question | Status |
|---|---|
| Does NNMT inhibition reduce fat mass in mice? | Published work says yes |
| Does 5-Amino-1MQ inhibit NNMT? | Yes, that is what it was developed as |
| Human trials at any dose | None found |
| Oral bioavailability in humans | Not established |
| Long-term safety | No data |
| What NNMT does elsewhere in the body long term | Not characterised |
Evidence status
The dosing figures
From vendor literature and community protocols, with the usual provenance caveat and one extra wrinkle.
The commonly cited figure is 50 to 150mg daily, taken orally. Those are much larger numbers than anything else in this catalogue, which sounds alarming until you remember it is a small molecule taken by mouth rather than a peptide injected in micrograms. Different class, different scale.
Cycles are usually described as eight to twelve weeks. As with every protocol in this field, that comes from community practice rather than from dose-finding work.
The oral route is also where the biggest unknown sits. Mouse studies deliver the compound in controlled ways; how much of an oral dose reaches circulation in a human has not been established, so the relationship between the number on the label and the exposure in your fat tissue is unknown.
Where it sits against the alternatives
If the goal is fat loss, the honest comparison is uncomfortable for this compound.
The GLP-1 medicines have phase 3 trial programmes and effect sizes nothing here approaches. Our peptides for weight loss page lays that out, including the fact that the same molecules are sold as research chemicals under code names.
5-Amino-1MQ's case is that it targets a different pathway, does not suppress appetite, and has a specific mechanism. Those are real points. They are not a substitute for human data, and anyone presenting the mouse results as a human result is overselling.
One practical note on buying it
Limitless gates every price behind an approved research account, so you cannot compare its cost against anything before registering. Our pricing gate page covers how that works and why our review carries no price for this vendor.
Everything referenced here is sold for research use only, and nothing on this page is medical advice.
